Please login to the form below

Not currently logged in
Email:
Password:

ArQule

This page shows the latest ArQule news and features for those working in and with pharma, biotech and healthcare.

AZ drug matched to cancer mutation passes phase 2 test

AZ drug matched to cancer mutation passes phase 2 test

A rival AKT inhibitor from BioOncology – ipatasertib – also reported positive data at ASCO from the mid-stage LOTUS trial in first-line TNBC with similar gains seen, while ArQule also has

Latest news

  • Roche drug fails in lung cancer trial Roche drug fails in lung cancer trial

    It remains to be seen whether the failed study has implications for other c-MET inhibitors in clinical trials, although the class has had other notable casualties, including ArQule's tivantinib

  • Daiichi, ArQule cancer drug tivantinib flunks another trial Daiichi, ArQule cancer drug tivantinib flunks another trial

    It is one of the first to emerge from a cancer collaboration between Daiichi and ArQule, which started in 2008. ... Shares in ArQule closed down more than 11 per cent on Friday on the announcement, as investors digested the news that tivantinib had

  • Russian market for lung cancer drugs to hit $163m by 2015

    The most dramatic growth will likely be seen in the kinase inhibitors drug class where three emerging agents - Boehringer Ingelheim's afitinib, Pfizer's dacomitinib and ArQule/Daiichi Sankyo/Kyowa Hakko

  • Non-small cell lung cancer research Non-small cell lung cancer research

    Another c-Met targeting drug currently under development is tivantinib, the result of a collaboration between ArQule, Daiichi Sankyo and Kyowa Hakko Kirin.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

  • X4 appoints John Celebi as COO X4 appoints John Celebi as COO

    Most recently, he served as chief business officer of Igenica Biotherapeutics, and has previously held senior positions at Agilent Technologies, ArQule, Biogen and Cyclis Pharmaceuticals.

  • Dr Jessie English joins Merck Dr Jessie English joins Merck

    During her two decades of work in oncology and immune-oncology research, she has also served as vice president of kinase biology at ArQule, oncology site lead for external discoveries at

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

Playing Mind Games
To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists
P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....

Infographics